In clinical practices, glioblastomas (GBM) in some cases can be misdiagnosed as sarcoidosis. This study aimed to develop a biomarker to distinguish GBM from sarcoidosis. In this study, we found that PSMG3-AS1 was upregulated in plasma of GBM patients in comparison with that in sarcoidosis patients and healthy controls. Receiver operating characteristic (ROC) curve analysis showed that upregulation of PSMG3-AS1 effectively separated GBM patients from sarcoidosis patients and healthy controls. In GBM cells, overexpression of PSMG3-AS1 led to downregulated miR-34a and increased methylation of miR-34a gene. In addition, overexpression of PSMG3-AS1 reduced the inhibitory effects of miR-34a on GBM cell proliferation. In conclusion, overexpression of PSMG3-AS1 distinguishes GBM patients from patients with sarcoidosis, and PSMG3-AS1 may promote GBM cell proliferation by downregulating miR-34a through methylation.

在临床实践中，胶质母细胞瘤（GBM）在某些情况下会被误诊为结节病。本研究旨在开发一种生物标志物来区分 GBM 和结节病。在这项研究中，我们发现与结节病患者和健康对照相比，GBM 患者血浆中的 PSMG3-AS1 上调。受试者工作特征（ROC）曲线分析表明，PSMG3-AS1 的上调有效地将 GBM 患者与结节病患者和健康对照区分开来。在 GBM 细胞中，PSMG3-AS1 的过表达导致 miR-34a 下调和 miR-34a 基因甲基化增加。此外，PSMG3-AS1的过表达降低了miR-34a对GBM细胞增殖的抑制作用。总之，PSMG3-AS1 的过表达将 GBM 患者与结节病患者区分开来，